Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

Vertex Pharmaceuticals (VRTX) is set to release its Q1 earnings report this Monday, with analysts anticipating a 6.5% year-on-year revenue growth. The company previously exceeded revenue expectations but missed EPS estimates. While the therapeutics segment shows positive investor sentiment, Vertex Pharmaceuticals’ stock is down 2.5% over the last month, trading below its average analyst price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin